What Does “Investigational New Drug (IND)” Status Actually Mean?
An Investigational New Drug (IND) application is a Food and Drug Administration (FDA) filing that lets a sponsor legally test an unapproved drug in humans. IND status means a product has permission to be studied under specific safety rules — not that regulators have confirmed it works, or that it’s approved for use outside a study.
You might see this phrase in marketing copy for a regenerative-medicine product — “IND-enabled,” “studied under an FDA IND,” or “investigational new drug status.” Knowing what that status covers, and what it doesn’t, helps you ask the right follow-up question before making a decision.
Where Does an IND Fit in the Drug Development Process?
An IND sits early in drug development — after animal testing and well before FDA marketing approval. Filing one gives a sponsor legal authorization to ship an unapproved drug to researchers and begin testing it in people, but a mandatory 30-day FDA safety review happens first.
- Preclinical testing. A sponsor tests the compound in animals to check for pharmacological activity and toxicity before it’s ever given to a person.
- IND application filed. This filing is what legally changes the product’s status to a “new drug” subject to federal drug-safety requirements, and allows it to be shipped to researchers across state lines.
- 30-day FDA safety review. After the IND is submitted, the sponsor must wait 30 calendar days before starting any clinical trial, giving the FDA a window to flag safety concerns.
- Clinical trial begins. If the FDA doesn’t place a hold on the study, researchers can start testing the drug in people under a specific, filed protocol.
- Possible future approval application. Only after trials produce results does a sponsor file a separate, later application for marketing approval. An active IND does not mean this step has happened.
What Are the Different Types of IND Filings?
The FDA recognizes three types of IND filings, each used in a different situation. Which type applies changes who is running the study and why it exists — information that matters more than the word “investigational” on its own.
| IND Type | Who Typically Files It | When It’s Used |
|---|---|---|
| Investigator IND | A physician who both initiates and personally conducts the study | To study an unapproved drug, or an approved drug for a new use or a new patient group |
| Emergency Use IND | Authorized by the FDA for an urgent situation | When there isn’t time to submit a standard IND before treatment is needed |
| Treatment IND | The drug’s sponsor | For a drug already showing promise in testing for a serious or life-threatening condition, while final trial work and FDA review continue |
INDs also fall into two categories: commercial, typically filed by a company developing a product toward eventual marketing, and research (non-commercial), typically filed by an individual investigator studying a scientific question rather than bringing a product to market.
What Information Must an IND Application Include?
Every IND application must include three types of information: preclinical data on animal safety, manufacturing details showing the drug can be produced consistently, and clinical protocols describing the planned human studies and the qualifications of the investigators running them. None of this reports outcomes in people — that’s what the trial itself is designed to find out.
- Animal pharmacology and toxicology data — to assess whether initial human testing is reasonably safe.
- Manufacturing information — covering composition, stability, and quality controls for the drug substance.
- Clinical protocols and investigator information — the planned study design and the credentials of the people overseeing it.
How Should You Evaluate IND Language as a Patient or Caregiver?
If you see IND language attached to a product or procedure, treat it as an invitation to ask questions, not as proof of safety or effectiveness. The specific IND type, trial phase, and consent process determine what you’d actually be agreeing to — none of that is implied by the word “investigational” alone.
If a clinic or product page describes something as “IND-enabled” or “under FDA investigational status,” then ask whether you’re being offered a role in a registered clinical trial, or simply being told the underlying drug has an active IND somewhere — these are not the same thing, and only the first involves a defined protocol and informed consent.
If you’re invited to participate in a study conducted under an IND, then ask for the written informed consent document and confirm an Institutional Review Board (IRB) has reviewed the study before agreeing to anything.
A short checklist to bring to that conversation:
- Is this product part of an active, registered clinical trial — or is the IND language describing something else?
- What IND type is this (Investigator, Emergency Use, or Treatment), and who is the sponsor?
- What phase is the trial in, and what has it found so far?
- Is there a written informed consent document, and has an IRB reviewed this study?
- Am I being offered a role as a research participant, or is this being marketed as an available treatment?
- Has this specific product received FDA marketing approval for any indication, or is it still investigational for all uses?
For a broader framework on how to read regenerative-medicine evidence claims in general — not just IND language specifically — see our Start Here guide.
Frequently Asked Questions About IND Language
Does “commercial IND” mean something different from “research IND”?
Yes. The FDA separates INDs into two categories: commercial, typically filed by a company developing a product toward eventual marketing, and research (non-commercial), typically filed by an individual investigator studying a scientific question rather than bringing a product to market. Knowing which category applies can clarify whose interests are driving a given study.
Is participating in a clinical trial run under an IND voluntary?
Yes. According to the FDA, participation in a clinical trial is always voluntary, and you can leave a study at any point, for any reason, even after enrolling.
Does the FDA’s 30-day review after an IND filing confirm the drug works?
No. The 30-day period lets the FDA review the application for safety concerns before human testing starts — not whether the drug is effective. Effectiveness is assessed later, using results gathered across the clinical trials themselves.
What is informed consent, and when do I receive it?
Informed consent is the process of explaining a study’s purpose, procedures, and risks to you before you agree to participate. The FDA’s guidance for patients specifies that this explanation happens before you agree to join, so you can decide with the actual study details in hand.
Where can I look up information about a specific clinical trial?
The FDA points people to ClinicalTrials.gov to search for studies by condition or drug name in their area. It’s a useful way to check whether a trial you’ve been told about is actually registered.
Sources and Limits of This Guide
This article is based on the FDA’s public descriptions of the Investigational New Drug (IND) Application process and the FDA’s Clinical Trial Participation guidance. It does not cover every IND scenario, does not evaluate any specific product or provider, and is not a substitute for individualized regulatory or legal advice. Regulatory processes can change; verify current requirements directly with the FDA or a qualified professional before making decisions. See our How We Research page and Editorial Policy for how sourcing standards like these are set and enforced across this site.
Educational information only. This article does not diagnose, recommend, or endorse any treatment, procedure, or product, and is not a substitute for advice from a licensed healthcare provider. If you are experiencing a medical emergency, contact local emergency services immediately. See our Medical Disclaimer for more, or use our Corrections page to flag anything that needs review.
Leave a Reply